NCT07083115Enrolling by invitation
Developing MRI Technologies for Atrial Fibrillation
Source: ClinicalTrials.gov · Last updated 23 Mar 2026
Brief summary (registry, in English)
To measure image quality of damaged areas of the heart in patients with Atrial fibrillation using the contrast Gadopiclenol vs conventional Gadolinium-based contrast agents(GBCA)
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 16 Jul 2025
- Start date
- 16 Jan 2025
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- The Cleveland Clinic
- Diseases
- Atrial fibrillation
- NCT number
- NCT07083115
What you commit to
- Study type: Observational
- Planned participants: 50
- From 16 Jan 2025 to the primary completion date, 30 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Contraindications to MRI
- Contraindications to Gadolinium based contrast agents.
Who the study is looking for
- -Diagnosis of Atrial Fibrillation
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cleveland Clinic Coordinator of this site? Confirm its status | Cleveland | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.